Leptomeningeal disease from oligodendroglioma: Clinical and molecular analysis

Canadian Journal of Neurological Sciences

Volumn 35, Issue 2, 2008, Pages 204-209

  Roldán, Gloria ^a,b   Scott, James ^a   George, David ^a   Parney, Ian ^a,b   Easaw, Jacob ^a,b   Cairncross, Gregory ^a,b   Forsyth, Peter ^a,b,c   Yan, Elizabeth ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b Clark Smith Integrated Brain Tumor Research Centre   (Canada)

^c Health Research Innovation Center   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CHLORAMBUCIL; ETOPOSIDE; PROCARBAZINE; TAMOXIFEN; TEMOZOLOMIDE; THIOTEPA; VINCRISTINE;

ADULT; ARTICLE; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOLOGY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENINGEAL METASTASIS; MOLECULAR GENETICS; MULTIPLE CYCLE TREATMENT; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PALLIATIVE THERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 45149121218     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100008647     Document Type: Article

References (18)

1. Bordignon K, Coelho M, Ramina R, Sousa de Meneses M, Zazula A, Morato L. Patterns of neuroaxis dissemination of gliomas: suggestion of a classification based on magnetic resonance imaging findings. Surg Neurol. 2006;65:472-7.
2. Ng HK, Sun DTF, Poon WS. Anaplastic oligodendroglioma with drop metastasis to the spinal cord. Clin Neurol Neurosurg. 2002;104:383-6.
3. Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM. Mork S, et al. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol. 2001;60:248-62.
4. Engelhard HH, Stelea A, Mundt A. Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment and prognosis. Surg Neurol. 2003;60:443-56.
5. Jukich PJ, McCarthy BJ, Surawicz TS, Freels S, Davis FG. Trends in incidence of primary brain tumors in the United States, 1985-1994. Neuro-oncol. 2001;3:141-51.
6. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707-14.
7. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715-22.
8. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66:9852-61.
9. Cairncross IG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-9.
10. Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys. 2000;48(3):825-30.
11. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 2001;7:839-45.
12. Vandenberg SR, Lopes MBS. Classification. In: Berger MS, Wilson CB, editors. The Gliomas. Philadelphia: WB Saunders; 1999: p. 181-84.
13. Reifenberger G, Kros JM, Burger PC, Louis DN, Colins VP. Oligodendroglioma. In: Kleihues P, Cavenee WK, editors. Pathology and genetics of tumours of the nervous system. 2nd ed. Lyon, France: IARC Press; 2000. p. 56-61.
14. Engelhard HH. Current diagnosis and treatment of oligodendroglioma. Neurosurg Focus. 2002;12:1-7.
15. Engelhard HH, Stelea A, Cochran EJ. Oligodendroglioma: pathology and molecular biology. Surg Neurol. 2002;57:111-7.
16. Seute T, Leffers P, Ten Velde G, Twijnstra A. Leptomeningeal metastases from small cell lung carcinoma frequencies and survival. Cancer. 2005;104:1700-5.
17. Yau T, Swanton C, Chua S, Sue A, Walsh G, Rostom A, et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol. 2006;45:196-201.
18. Puente Vazquez J, Lopez-Tarruella Cobo S, Garcia-Saenz JA, Casado Herraez A, Moreno Anton F, Sampedro Gimeno T, et al. Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies. Clin Transl Oncol. 2006;8:50-3.